LG Chem announced on the 9th that it held the LGS (LG Growth Study) symposium on the 7th for pediatric growth specialists and presented the interim analysis results of the Utrophin product line observational study, a long-term prospective study targeting children with short stature in Korea.
LG Chem has been conducting research since 2012 to secure long-term growth hormone administration data for Korean children for the first time in the country. This large-scale study recruited 10,000 patients over 20 years until last year to observe long-term safety and efficacy. At this symposium, LG Chem deeply analyzed the accumulated results up to last year, attracting the audience's attention.
At the event, Professor Kim Ja-hye of Seoul Asan Medical Center analyzed under the theme "Utrophin 11th Year Safety and Efficacy Interim Analysis Results" that Utrophin safely and effectively improved height growth in children with short stature. Tracking about 6,000 registered patients, clinically favorable safety was confirmed, and in terms of efficacy, improvement in growth rate was observed not only in patients with growth hormone deficiency, Turner syndrome, and small for gestational age (low birth weight) but also in patients with idiopathic short stature who have normal growth hormone secretion.
Based on this accumulated long-term research data, LG Chem plans to develop a growth prediction model specialized for Korean children and actively contribute to improving the treatment environment for short stature by continuously supporting physicians' academic activities.
Park Hee-sul, Executive Vice President and Head of LG Chem Specialty-Care Division, said, "As a partner accompanying the long-term treatment journey of children with short stature, we will continue various studies to establish trust in growth hormone treatment."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
